Eiger BioPharmaceuticals (EIGR) Reports Complete Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients
Tweet Send to a Friend
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) announced completion of enrollment of the Phase 2 ULTRA study. ULTRA is a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
